Phase III study of the European Organisation for research and Treatment of Cancer Quality of Life cancer survivorship core questionnaire

Marieke Van leeuwen; Jacobien m. Kieffer; Teresa Young; Maria antonietta Annunziata; Volker Arndt; Juan ignacio Arraras; Didier Autran; Hira bani Hani; Manas Chakrabarti; Olivier Chinot; Juhee Cho; Rene aloisio Da costa vieira; Anne-Sophie Darlington; Philip r. Debruyne; Linda Dirven; Daniela Doege; Yannick Eller; Martin Eichler; Nanna Fridriksdottir; Ioannis Gioulbasanis; Eva Hammerlid; Mieke Van hemelrijck; Silke Hermann; Olga Husson; Michael Jefford; Christoffer Johansen; Trille kristina Kjaer; Meropi Kontogianni; Pernilla Lagergren; Emma Lidington; Karolina Lisy; Ofir Morag; Andy Nordin; Amal s.h. Al omari; Andrea Pace; Silvia De padova; Duska Petranovia; Monica Pinto; John Ramage; Elke Rammant; Jaap Reijneveld; Samantha Serpentini; Sam Sodergren; Vassilios Vassiliou; Irma verdonck-De Leeuw; Ingvild Vistad; Teresa Young; Neil k. Aaronson; L.V. van de Poll-Franse

doi:10.1007/s11764-021-01160-1

Phase III study of the European Organisation for research and Treatment of Cancer Quality of Life cancer survivorship core questionnaire

Marieke Van leeuwen, Jacobien m. Kieffer, Teresa Young, Maria antonietta Annunziata, Volker Arndt, Juan ignacio Arraras, Didier Autran, Hira bani Hani, Manas Chakrabarti, Olivier Chinot, Juhee Cho, Rene aloisio Da costa vieira, Anne-Sophie Darlington, Philip r. Debruyne, Linda Dirven, Daniela Doege, Yannick Eller, Martin Eichler, Nanna Fridriksdottir, Ioannis GioulbasanisEva Hammerlid, Mieke Van hemelrijck, Silke Hermann, Olga Husson, Michael Jefford, Christoffer Johansen, Trille kristina Kjaer, Meropi Kontogianni, Pernilla Lagergren, Emma Lidington, Karolina Lisy, Ofir Morag, Andy Nordin, Amal s.h. Al omari, Andrea Pace, Silvia De padova, Duska Petranovia, Monica Pinto, John Ramage, Elke Rammant, Jaap Reijneveld, Samantha Serpentini, Sam Sodergren, Vassilios Vassiliou, Irma verdonck-De Leeuw, Ingvild Vistad, Teresa Young, Neil k. Aaronson, L.V. van de Poll-Franse

Medical and Clinical Psychology

Research output: Contribution to journal › Article › Scientific › peer-review

4 Downloads (Pure)

Abstract

Purpose
The purpose of this study is to develop a European Organisation for Research and Treatment of Cancer Quality of Life Group (EORTC QLG) questionnaire that captures the full range of physical, mental, and social health-related quality of life (HRQOL) issues relevant to disease-free cancer survivors. In this phase III study, we pretested the provisional core questionnaire (QLQ-SURV111) and aimed to identify essential and optional scales.

Methods
We pretested the QLQ-SURV111 in 492 cancer survivors from 17 countries with one of 11 cancer diagnoses. We applied the EORTC QLG decision rules and employed factor analysis and item response theory (IRT) analysis to assess and, where necessary, modify the hypothesized questionnaire scales. We calculated correlations between the survivorship scales and the QLQ-C30 summary score and carried out a Delphi survey among healthcare professionals, patient representatives, and cancer researchers to distinguish between essential and optional scales.

Results
Fifty-four percent of the sample was male, mean age was 60 years, and, on average, time since completion of treatment was 3.8 years. Eleven items were excluded, resulting in the QLQ-SURV100, with 12 functional and 9 symptom scales, a symptom checklist, 4 single items, and 10 conditional items. The essential survivorship scales consist of 73 items.

Conclusions
The QLQ-SURV100 has been developed to assess comprehensively the HRQOL of disease-free cancer survivors. It includes essential and optional scales and will be validated further in an international phase IV study.

Original language	English
Pages (from-to)	1111-1130
Journal	Journal of Cancer Survivorship
Volume	17
DOIs	https://doi.org/10.1007/s11764-021-01160-1
Publication status	Published - 2023

Access to Document

10.1007/s11764-021-01160-1

Phase III study of the European Organisation for research and Treatment of Cancer Quality of Life cancer survivorship core questionnaireFinal published version, 889 KBLicence: Taverne

https://link.springer.com/10.1007/s11764-021-01160-1

Cite this

Van leeuwen, M., Kieffer, J. M., Young, T., Annunziata, M. A., Arndt, V., Arraras, J. I., Autran, D., Hani, H. B., Chakrabarti, M., Chinot, O., Cho, J., Da costa vieira, R. A., Darlington, A.-S., Debruyne, P. R., Dirven, L., Doege, D., Eller, Y., Eichler, M., Fridriksdottir, N., ... van de Poll-Franse, L. V. (2023). Phase III study of the European Organisation for research and Treatment of Cancer Quality of Life cancer survivorship core questionnaire. Journal of Cancer Survivorship, 17, 1111-1130. https://doi.org/10.1007/s11764-021-01160-1

@article{1226e0897c6f448db38685249755a4a8,

title = "Phase III study of the European Organisation for research and Treatment of Cancer Quality of Life cancer survivorship core questionnaire",

abstract = "PurposeThe purpose of this study is to develop a European Organisation for Research and Treatment of Cancer Quality of Life Group (EORTC QLG) questionnaire that captures the full range of physical, mental, and social health-related quality of life (HRQOL) issues relevant to disease-free cancer survivors. In this phase III study, we pretested the provisional core questionnaire (QLQ-SURV111) and aimed to identify essential and optional scales.MethodsWe pretested the QLQ-SURV111 in 492 cancer survivors from 17 countries with one of 11 cancer diagnoses. We applied the EORTC QLG decision rules and employed factor analysis and item response theory (IRT) analysis to assess and, where necessary, modify the hypothesized questionnaire scales. We calculated correlations between the survivorship scales and the QLQ-C30 summary score and carried out a Delphi survey among healthcare professionals, patient representatives, and cancer researchers to distinguish between essential and optional scales.ResultsFifty-four percent of the sample was male, mean age was 60 years, and, on average, time since completion of treatment was 3.8 years. Eleven items were excluded, resulting in the QLQ-SURV100, with 12 functional and 9 symptom scales, a symptom checklist, 4 single items, and 10 conditional items. The essential survivorship scales consist of 73 items.ConclusionsThe QLQ-SURV100 has been developed to assess comprehensively the HRQOL of disease-free cancer survivors. It includes essential and optional scales and will be validated further in an international phase IV study.",

author = "{Van leeuwen}, Marieke and Kieffer, {Jacobien m.} and Teresa Young and Annunziata, {Maria antonietta} and Volker Arndt and Arraras, {Juan ignacio} and Didier Autran and Hani, {Hira bani} and Manas Chakrabarti and Olivier Chinot and Juhee Cho and {Da costa vieira}, {Rene aloisio} and Anne-Sophie Darlington and Debruyne, {Philip r.} and Linda Dirven and Daniela Doege and Yannick Eller and Martin Eichler and Nanna Fridriksdottir and Ioannis Gioulbasanis and Eva Hammerlid and {Van hemelrijck}, Mieke and Silke Hermann and Olga Husson and Michael Jefford and Christoffer Johansen and Kjaer, {Trille kristina} and Meropi Kontogianni and Pernilla Lagergren and Emma Lidington and Karolina Lisy and Ofir Morag and Andy Nordin and {Al omari}, {Amal s.h.} and Andrea Pace and {De padova}, Silvia and Duska Petranovia and Monica Pinto and John Ramage and Elke Rammant and Jaap Reijneveld and Samantha Serpentini and Sam Sodergren and Vassilios Vassiliou and Leeuw, {Irma verdonck-De} and Ingvild Vistad and Teresa Young and Aaronson, {Neil k.} and {van de Poll-Franse}, L.V.",

year = "2023",

doi = "10.1007/s11764-021-01160-1",

language = "English",

volume = "17",

pages = "1111--1130",

journal = "Journal of Cancer Survivorship",

issn = "1932-2259",

publisher = "Springer New York",

}

Van leeuwen, M, Kieffer, JM, Young, T, Annunziata, MA, Arndt, V, Arraras, JI, Autran, D, Hani, HB, Chakrabarti, M, Chinot, O, Cho, J, Da costa vieira, RA, Darlington, A-S, Debruyne, PR, Dirven, L, Doege, D, Eller, Y, Eichler, M, Fridriksdottir, N, Gioulbasanis, I, Hammerlid, E, Van hemelrijck, M, Hermann, S, Husson, O, Jefford, M, Johansen, C, Kjaer, TK, Kontogianni, M, Lagergren, P, Lidington, E, Lisy, K, Morag, O, Nordin, A, Al omari, ASH, Pace, A, De padova, S, Petranovia, D, Pinto, M, Ramage, J, Rammant, E, Reijneveld, J, Serpentini, S, Sodergren, S, Vassiliou, V, Leeuw, IV-D, Vistad, I, Young, T, Aaronson, NK & van de Poll-Franse, LV 2023, 'Phase III study of the European Organisation for research and Treatment of Cancer Quality of Life cancer survivorship core questionnaire', Journal of Cancer Survivorship, vol. 17, pp. 1111-1130. https://doi.org/10.1007/s11764-021-01160-1

TY - JOUR

T1 - Phase III study of the European Organisation for research and Treatment of Cancer Quality of Life cancer survivorship core questionnaire

AU - Van leeuwen, Marieke

AU - Kieffer, Jacobien m.

AU - Young, Teresa

AU - Annunziata, Maria antonietta

AU - Arndt, Volker

AU - Arraras, Juan ignacio

AU - Autran, Didier

AU - Hani, Hira bani

AU - Chakrabarti, Manas

AU - Chinot, Olivier

AU - Cho, Juhee

AU - Da costa vieira, Rene aloisio

AU - Darlington, Anne-Sophie

AU - Debruyne, Philip r.

AU - Dirven, Linda

AU - Doege, Daniela

AU - Eller, Yannick

AU - Eichler, Martin

AU - Fridriksdottir, Nanna

AU - Gioulbasanis, Ioannis

AU - Hammerlid, Eva

AU - Van hemelrijck, Mieke

AU - Hermann, Silke

AU - Husson, Olga

AU - Jefford, Michael

AU - Johansen, Christoffer

AU - Kjaer, Trille kristina

AU - Kontogianni, Meropi

AU - Lagergren, Pernilla

AU - Lidington, Emma

AU - Lisy, Karolina

AU - Morag, Ofir

AU - Nordin, Andy

AU - Al omari, Amal s.h.

AU - Pace, Andrea

AU - De padova, Silvia

AU - Petranovia, Duska

AU - Pinto, Monica

AU - Ramage, John

AU - Rammant, Elke

AU - Reijneveld, Jaap

AU - Serpentini, Samantha

AU - Sodergren, Sam

AU - Vassiliou, Vassilios

AU - Leeuw, Irma verdonck-De

AU - Vistad, Ingvild

AU - Young, Teresa

AU - Aaronson, Neil k.

AU - van de Poll-Franse, L.V.

PY - 2023

Y1 - 2023

N2 - PurposeThe purpose of this study is to develop a European Organisation for Research and Treatment of Cancer Quality of Life Group (EORTC QLG) questionnaire that captures the full range of physical, mental, and social health-related quality of life (HRQOL) issues relevant to disease-free cancer survivors. In this phase III study, we pretested the provisional core questionnaire (QLQ-SURV111) and aimed to identify essential and optional scales.MethodsWe pretested the QLQ-SURV111 in 492 cancer survivors from 17 countries with one of 11 cancer diagnoses. We applied the EORTC QLG decision rules and employed factor analysis and item response theory (IRT) analysis to assess and, where necessary, modify the hypothesized questionnaire scales. We calculated correlations between the survivorship scales and the QLQ-C30 summary score and carried out a Delphi survey among healthcare professionals, patient representatives, and cancer researchers to distinguish between essential and optional scales.ResultsFifty-four percent of the sample was male, mean age was 60 years, and, on average, time since completion of treatment was 3.8 years. Eleven items were excluded, resulting in the QLQ-SURV100, with 12 functional and 9 symptom scales, a symptom checklist, 4 single items, and 10 conditional items. The essential survivorship scales consist of 73 items.ConclusionsThe QLQ-SURV100 has been developed to assess comprehensively the HRQOL of disease-free cancer survivors. It includes essential and optional scales and will be validated further in an international phase IV study.

AB - PurposeThe purpose of this study is to develop a European Organisation for Research and Treatment of Cancer Quality of Life Group (EORTC QLG) questionnaire that captures the full range of physical, mental, and social health-related quality of life (HRQOL) issues relevant to disease-free cancer survivors. In this phase III study, we pretested the provisional core questionnaire (QLQ-SURV111) and aimed to identify essential and optional scales.MethodsWe pretested the QLQ-SURV111 in 492 cancer survivors from 17 countries with one of 11 cancer diagnoses. We applied the EORTC QLG decision rules and employed factor analysis and item response theory (IRT) analysis to assess and, where necessary, modify the hypothesized questionnaire scales. We calculated correlations between the survivorship scales and the QLQ-C30 summary score and carried out a Delphi survey among healthcare professionals, patient representatives, and cancer researchers to distinguish between essential and optional scales.ResultsFifty-four percent of the sample was male, mean age was 60 years, and, on average, time since completion of treatment was 3.8 years. Eleven items were excluded, resulting in the QLQ-SURV100, with 12 functional and 9 symptom scales, a symptom checklist, 4 single items, and 10 conditional items. The essential survivorship scales consist of 73 items.ConclusionsThe QLQ-SURV100 has been developed to assess comprehensively the HRQOL of disease-free cancer survivors. It includes essential and optional scales and will be validated further in an international phase IV study.

U2 - 10.1007/s11764-021-01160-1

DO - 10.1007/s11764-021-01160-1

M3 - Article

SN - 1932-2259

VL - 17

SP - 1111

EP - 1130

JO - Journal of Cancer Survivorship

JF - Journal of Cancer Survivorship

ER -

Phase III study of the European Organisation for research and Treatment of Cancer Quality of Life cancer survivorship core questionnaire

Abstract

Access to Document

Fingerprint

Cite this